Vir Biotechnology (VIR) Other Accumulated Expenses (2018 - 2023)

Vir Biotechnology has reported Other Accumulated Expenses for 6 years, with the latest figure at $9.7 million in Q1 2023.

• Quarterly Other Accumulated Expenses fell 90.59% year-over-year to $9.7 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $9.7 million (down 90.59% YoY) and the FY2022 annual result came in at $12.7 million, up 23.96% from the prior year.
• Other Accumulated Expenses slipped to $9.7 million in Q1 2023 per VIR's latest filing, from $12.7 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $103.3 million in Q1 2022 and troughed at $595000.0 in Q2 2020.
• A 5-year average of $13.4 million and a median of $3.3 million in 2021 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2022 and 2023: Other Accumulated Expenses jumped 5910.47% in 2022, then plunged 90.59% in 2023.
• Over 5 years, Other Accumulated Expenses stood at $1.2 million in 2019, then sank by 30.36% to $805000.0 in 2020, then jumped by 1173.79% to $10.3 million in 2021, then climbed by 23.96% to $12.7 million in 2022, then dropped by 23.53% to $9.7 million in 2023.
• According to Business Quant data, Other Accumulated Expenses over the past three periods registered $9.7 million, $12.7 million, and $27.8 million for Q1 2023, Q4 2022, and Q3 2022 respectively.